CG011231

CG011231 is an investigational degrader-antibody conjugate (DAC) being developed by Cullgen for the treatment of various oncology indications. This therapeutic modality represents a hybrid approach that combines the high specificity of a monoclonal antibody with the catalytic potency of a targeted protein degrader (TPD) payload. By utilizing an antibody to deliver the degrader specifically to cancer cells, CG011231 is designed to trigger the selective intracellular degradation of a disease-relevant protein. This mechanism potentially offers a wider therapeutic window and enhanced efficacy compared to traditional antibody-drug conjugates (ADCs). As of the current pipeline disclosure, the specific molecular target and the nature of the degrader payload remain undisclosed.